2359 logo

2359

药明康德 · Hong Kong StocksTradingView Chart ↗
Signal return
+10.90%
Price move
+31.63%(HK$48.4)
First included
2026-07-18
Inclusion price
HK$153
Latest brief price
HK$201.4

Methodology: each issue's direction is a live signal — long/short opens or holds a position, neutral means flat, and every direction change opens, flips, or closes it. Returns are direction-aware (a short gains when the price falls) and compound across positions from first observation to the latest issue. "Price move" is the stock's own raw change, shown separately. Neither represents actual portfolio performance.

Position History1/1 closed trades won · profitable since 2026-08-05

  • 2026-08-04LongHK$181.6 → closed HK$201.42026-08-13+10.90%

Brief History (9 issues)

August 13, 2026NeutralDeep dive7/10HK$201.4+1.26%

Position review verdict: close out and book profits. Yesterday's long signal has fully paid off — the earnings beat, the injunction win and the wave of target hikes have all landed, and momentum is stalling after the Aug 10 record high: RSI 80.3 / RSI-7 87.5 are severely overbought, the close sits 17.5% above the 20-day SMA, 10-day relative volume has shriveled to 0.14, the stock is 1.6% from its HK$204.6 52-week high, and the HK$219 consensus target leaves only 8.7% — with CICC/Jefferies' fresh targets (211/210) practically at the doorstep. High-altitude consolidation on fading volume after catalysts are spent is a textbook profit-taking zone. Reference levels: reassess a fresh long if a pullback stabilizes on light volume in HK$172-185 (between the 20-day SMA at 171.4 and close minus 2x ATR at 184.3); a break below HK$168 (~2% under the 20-day SMA) would damage the trend structure.

August 12, 2026LongDeep dive8/10HK$199.1+0.56%

Position maintained — but this is a holding where the exit cadence deserves thought. Fundamentals and legal risk turning together is genuinely rare, and a 14% guidance raise is not yet fully digested, so the direction stays bullish. The issue is the odds: RSI(7) at 86.8, a 52-week high 2.7% overhead, and only 5-6% to the major houses' targets. After that triple compression, upside needs a new catalyst while the good news was all released inside five sessions. Do not chase; HK$180-190 on a pullback is the add zone. Stop at HK$176, about 2.5 ATR below, target HK$218 at consensus. The next event window is OMB's BCC list, due before December.

August 11, 2026LongDeep dive9/10HK$202+2.02%

Fundamentals and legal risk turned in the same week, making the long thesis firmer than last period — the position stays. But RSI(7) at 87.9 and a 52-week high just 1.1% overhead mark this as the strongest trend at the worst odds; the cleaner add is HK$185-193, between spot and the 20-day at HK$167.92. Stop below the 20-day at HK$167, target HK$225 on the measured move through the high.

August 8, 2026LongDeep dive8/10HK$192.3+7.01%

Maintaining the long with chasing explicitly ruled out. The fundamentals are beyond reproach: a single-step guidance raise of more than RMB7B, with the sector delivering earnings together. But two constraints tightened at once — RSI(7) at 84.0 is deeply overbought and consensus upside compressed from 20.1% to 11.2%. The stop rises from HK$162 to HK$168 to lock in most of this leg, the entry zone moves up to HK$176–184, and the target stays HK$213 on consensus. Being 0.4% below the 52-week high means there are no trapped holders overhead for reference, so post-breakout action lacks predictable resistance — which is both the opportunity and the risk.

August 7, 2026LongDeep dive8/10HK$178-0.95%

Maintaining the long. Today's signal is healthy: RSI(7) fell from 86.7 to 71.2, digesting the overbought condition while price gave up only 0.95% — far better than working it off through a selloff. Falling less than the index on a day the Hang Seng dropped 1.49% and southbound flipped to selling indicates a stable shareholder base. The entry guidance shifts from yesterday's do-not-add to an actual HK$168–176 pullback zone (the earlier HK$168–175 was never touched), the stop stays at HK$162, and the target rises to HK$213 following consensus up from HK$208. RSI at 68.9 is still elevated, which is why this stays lean bullish rather than bullish.

August 6, 2026LongDeep dive8/10HK$183.5+1.33%

A powerful trend, but RSI(7) 87.3 is deeply overbought — don't chase. Wait for a pullback near the SMA20 (HK$160) to add, stop at HK$160. Holders should sit tight; a break of the HK$188 prior high opens HK$200.

August 5, 2026LongDeep dive8/10HK$182.2+0.61%

Maintaining the long but stepping down from bullish to lean bullish — on price, not thesis. Consensus targets rose from HK$188.77 to HK$208.74 in a single day, showing analysts chasing the fundamentals, which is healthy. But RSI(7) at 86.7 means any good news landing can trigger profit-taking. The stop moves up to HK$162 at the lower edge of the consolidation above the 20-day, with a target of HK$208 from freshly raised consensus. Yesterday's HK$168–175 pullback zone never arrived, confirming unusual strength — but a missed entry zone should never be replaced by chasing.

August 4, 2026LongDeep dive9/10HK$181.6+11.48%

The fundamental gear change is real: Q2 growth accelerating to 47.71%, backlog up 25.2%, and a single-shot guidance raise of more than RMB7B — a signal worth booking. But RSI(7) at 86.4 plus a 14% gap on 8/4 morning makes chasing terrible risk/reward. The HK$168–175 zone, the prior breakout shelf above the 20-day, is the rational entry, with a stop at HK$157 below the 20-day at HK$158.18 and a measured target of HK$205 above the 52-week high.

July 18, 2026NeutralRapid scan6/10HK$153-5.56%

Down 5.56% to HK$153 as CXO got hit across the board — a +22.9% month handed profit-takers their exit ticket. Not catching this until the unwind runs its course.

2359 药明康德 Analysis: Brief History, Signals & Track Record · Quant Brief